Abstract
Abstract Background Not much is known about the local prevalence of cutaneous fungal infections in Canada because these data are not readily available. Knowing the distribution of microorganisms in local settings may help developing guidance for empiric therapy, especially for immunocompromised patients whose cutaneous fungal infections could turn into systemic infections. The current retrospective study aimed to establish the prevalence and distribution of fungal microorganisms among patients who had specimens submitted to community microbiology laboratory for cutaneous fungal culture workups. Methods LifeLabs regional microbiology laboratories, connected with 129 collection centers in urban and rural communities in British Columbia, provided reports of isolated fungus from hair, nail, and skin scraping specimens from 1 January 2022 to 31 December 2022. Culture followed by microscopy and/or MALDI-TOF mass spectrometry was routinely used to isolate and identity microorganisms, but nucleic-acid testing was added to help identification if needed. Results Among the 20652 cutaneous specimens submitted in a year, 3665 of them were reported to have microorganism growth. The most reported microorganism was Trichophyton species (43.8%), followed by Penicillium species (5.8%), Candida albicans (4.2%), Aspergillus species (3.6%), and Fusarium species (2.8%). Of note, other than Trichophyton species, the other two main dermatophytes Microsporum species and Epidermophyton species accounted for only 0.2% and 0.1% of the positive specimens, respectively. Pseudomonas aeruginosa was incidentally identified in 2.9% of the positive specimens in the fungal culture workups. Conclusion Trichophyton species was the most reported microorganism among the hair, nail, and skin scrapping specimens submitted for cutaneous fungal culture workups from communities in British Columbia. Pseudomonas infections, which could present as chloronychia, folliculitis, ecthyma gangrenosum, could be considered in the differential diagnoses of cutaneous fungal infections. The current data will help clinicians to determine the empiric therapy needed based on each patient’s clinical situation. Disclosures All Authors: No reported disclosures
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have